MarketPulse
E

$EXEL

3 articles found
3 positive
0 negative
0 neutral
BenzingaBenzinga··Vandana Singh

Merck Tumbles 4% as Cancer Trial Fails, Though HIV Approval Offers Lifeline

Merck shares dropped 4% after Phase 3 cancer trial failure, but FDA approval of HIV treatment Idvynso provided partial offset.
MRKEXELFDA approvalclinical trial failure
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Three Sub-$50 Healthcare Stocks Poised for Growth in Pharma, Oncology Sectors

Three healthcare stocks under $50 offer distinct value: Pfizer at $27.45 with 9x P/E and strong oncology pipeline; Novo Nordisk at $38.43 capitalizing on weight-loss drugs; Exelixis at $41.80 with proven oncology franchise.
PFENVOEXELvaluationbiotech
The Motley FoolThe Motley Fool··James Halley

Exelixis Expands Beyond Cabozantinib With FDA Approval and Robust Pipeline

Exelixis secures FDA approval for zanzalintinib and expands beyond cabozantinib with robust pipeline, posting 57.9% EPS growth while advancing multiple Phase 3 trials.
MRKNTRAEXELFDA approvalbiotech